Anavex Life Sciences Corp (AVXL)

[Steady_T]

Biogen looked at 2-73 for a very specific application namely MS.

There are many reasons that Biogen may have for not pursuing 2-73 including that potentiating myelin growth is not sufficient to treat MS.

MS is an autoimmune disease. Which suggests that unless something suppresses the ongoing attack of myelin a drug that causes growth of myelin is at best in a race to cause growth faster than the immune system destroys it.

2-73 might well be a good drug for MS after some other approach to prevent the immune system from attacking myelin. That might turn out to be another gut biome issue. Who knows?